Advanced search
Add to list

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients

Author
Organization

Citation

Please use this url to cite or link to this publication:

MLA
Vander Cruyssen, Bert, et al. “Das28 Correlates Best with the Physician’s Clinical Judgment of Response to Infliximab Therapy in Rheumatoid Arthritis Patients.” ANNALS OF THE RHEUMATIC DISEASES, vol. 64, B M J PUBLISHING GROUP, 2005, pp. 187–88.
APA
Vander Cruyssen, B., Van Looy, S., WESTHOVENS, R., DUREZ, P., Van den Bosch, F., VEYS, E., … De Keyser, F. (2005). Das28 correlates best with the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients. In ANNALS OF THE RHEUMATIC DISEASES (Vol. 64, pp. 187–188). B M J PUBLISHING GROUP.
Chicago author-date
Vander Cruyssen, Bert, Stijn Van Looy, R WESTHOVENS, P DUREZ, Filip Van den Bosch, EM VEYS, L DE CLERCK, et al. 2005. “Das28 Correlates Best with the Physician’s Clinical Judgment of Response to Infliximab Therapy in Rheumatoid Arthritis Patients.” In ANNALS OF THE RHEUMATIC DISEASES, 64:187–88. B M J PUBLISHING GROUP.
Chicago author-date (all authors)
Vander Cruyssen, Bert, Stijn Van Looy, R WESTHOVENS, P DUREZ, Filip Van den Bosch, EM VEYS, L DE CLERCK, A PERETZ, M MALAISE, J DEVOGELAER, L VERBRUGGEN, N VASTESAEGER, A GELDHOF, L BOULART, and Filip De Keyser. 2005. “Das28 Correlates Best with the Physician’s Clinical Judgment of Response to Infliximab Therapy in Rheumatoid Arthritis Patients.” In ANNALS OF THE RHEUMATIC DISEASES, 64:187–188. B M J PUBLISHING GROUP.
Vancouver
1.
Vander Cruyssen B, Van Looy S, WESTHOVENS R, DUREZ P, Van den Bosch F, VEYS E, et al. Das28 correlates best with the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients. In: ANNALS OF THE RHEUMATIC DISEASES. B M J PUBLISHING GROUP; 2005. p. 187–8.
IEEE
[1]
B. Vander Cruyssen et al., “Das28 correlates best with the physician’s clinical judgment of response to infliximab therapy in rheumatoid arthritis patients,” in ANNALS OF THE RHEUMATIC DISEASES, 2005, vol. 64, pp. 187–188.
@inproceedings{329500,
  author       = {{Vander Cruyssen, Bert and Van Looy, Stijn and WESTHOVENS, R and DUREZ, P and Van den Bosch, Filip and VEYS, EM and DE CLERCK, L and PERETZ, A and MALAISE, M and DEVOGELAER, J and VERBRUGGEN, L and VASTESAEGER, N and GELDHOF, A and BOULART, L and De Keyser, Filip}},
  booktitle    = {{ANNALS OF THE RHEUMATIC DISEASES}},
  issn         = {{0003-4967}},
  language     = {{eng}},
  pages        = {{187--188}},
  publisher    = {{B M J PUBLISHING GROUP}},
  title        = {{Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients}},
  volume       = {{64}},
  year         = {{2005}},
}

Web of Science
Times cited: